Eric Malzone: Everybody, welcome to the Future of Fitness, a top-rated fitness industry podcast for over four years and running. I'm your host, Eric Malzone, and I have the absolute pleasure of talking to entrepreneurs, executives, thought leaders, and cutting-edge technology experts within the extremely fast-paced industries of fitness, wellness, and health sciences. Please stop by futurofitness.co to subscribe and get our interviews and summaries delivered straight to your inbox. You'll also find our free industry report on artificial intelligence. Five industry experts, five different opinions, and tons of valuable insights for free at futurofitness.co. Thanks for listening and on to the show.
Eric Malzone: Traditional advertising isn't what it used to be. Costs are high, consumer trust is low. See the results firsthand and can assure you there's a much better way to connect with your target audience and emerge as a thought leader in our industry. That's exactly why I've launched the podcast collective. The ultimate solution designed to empower executives, founders, and thought leaders in the fittest health and wellness sectors. Our mission? To help you leverage the extraordinary opportunities within our hand-picked network of independent podcasts. We don't just place you on podcasts, we make you unforgettable. One-on-one coaching ensures that you show up the right message for the right audience with confidence and swagger. We create high-popping digital assets and social media overhauls to ensure that you are optimizing each and every appearance. Key introductions to strategic partners and potential enterprise clients provide unparalleled value that only a professional network like ours can offer. We work with a very limited number of clients to ensure the highest level of service,
Eric Malzone: so please don't hesitate to reach out and learn more. Go to podcastcollective.io to learn more and contact me directly. That's podcastcollective.io. Well, we are live. Uh for Smith, man. Welcome to the future of fitness.
Thank you for having me here, Eric. I'm I'm uh I really appreciate the opportunity to come and talk to you and your your followers.
Eric Malzone: Yeah, it's uh red light. Like I, as we were just chatting, I'm generally so curious about it. I think it's not talked about. I mean, given what I've researched and I was telling you, I was just sort of using a little bit with a red light panel. So I'm trying to, you know, figuring out for myself and you know, uh, n equals one sample size over here. But you know, you you obviously live in that world. You're a believer in the technology, uh, what you guys are doing at your company. It seems really exciting. And yeah, so anyway, I'm gonna stop talking and let's let's get into you force. Maybe just give us a little bit of your background, you know, how you got to be where you are and and and the company, and then we'll take it from there.
Sure. My my personal background has been starting startups since I was about 20 or 21. Uh, and those have kind of gotten uh starting and build it and then then uh exit in most cases. But this one's actually really uh a little bit closer to home uh for us because I I having done that a few cycles, my partner and I actually met by way of talking about the same type of thing on different in on different sides of the planet. And so what we what we both wanted to do was build a business that was less focused on the commercial outcome and more on the systemic impact, where we can come in and have a real meaningful impact on not just our own internal stakeholders, but on kind of the systemic outcomes uh for health and wellness for for a larger uh number of people. And we spent our first two months together sitting down and going through and talking about how can we do that in a way that still holds us accountable. And so what it's come down to in the end for us, which is our our kind of true north, our compass for as a company, for every decision that we make is our mission
is to increase the quality of life for the largest number of people we can in the most measurable way we can. And uh, you know, our our first product is a neuromuscular pain and inflammation device that's uh working to do just that. So there's when we launched the company, there was really no laser therapy devices available uh outside of clinical settings. And in I I spend a ton of time in the medical literature, kind of reading behind whether it's health and performance or metabolic modeling, really things that are going to be kind of high-leverage spins uh from a research standpoint and that you can apply whether it's your training or diet or uh recovery modalities, et cetera. And one of the ones that we'd seen really powerful data around was laser therapy, but it was very limited in what was available from a product standpoint. And I, you know, the the there's some very good clinical device manufacturers out there uh like Thor Laser. Uh James Carroll's done a great job getting these out there. And and they're they're in you know many different uh NFL facilities or or clinical level applications,
but they're they're $30,000. And you know, our assumption was that if people are using uh pharmaceuticals to treat their pain and inflammation right now, A, it's because they don't know how damaging those pharmaceuticals are to their their physiology, there needs to be an education around this. But B, we can actually make a systemic impact and give them an alternative if we can reduce the price, reduce the size, take these big desktop devices and make it into something that's battery-driven and wearable so that people can build habits on a day-to-day basis around reducing the pain and inflammation in their joints. And, you know, uh it's uh it's so our first product has has been essentially around around that. How do we how do we reduce friction points for people? How do we reduce cost? And how do we provide an alternative to things again that in line with our mission where there's a big gap between the technology that exists and what's been adopted and the education piece around that?
Eric Malzone: Awesome. How do you say the name of your company? How do you pronounce it? Uh, Kinyan.
It's it's from the uh Greek for movement.
Eric Malzone: Oh, really? Oh, cool. I love that that's cool. Can you maybe give us a little bit of history into red light therapy, laser therapy, stuff like that? Like how long has it been around? You know, it's always like early adopters tend to be biohackers, right for lack of a better term, in that. So maybe give us a a kind of a history and then we can get into exactly what you guys are doing.
Absolutely. So there's there's really good uh data from from ages ago, hundreds of years ago, on light and how light affects things like seasonal affective disorder and and people's moods. Uh so we we've always kind of known that there are uh we always had the, I think from a scientific standpoint, had the idea that there are photo acceptors in our body that are triggering different signaling pathways from light. Uh, one of the things that's that's not been there until more recently is the emitters. Uh and so really you didn't see kind of the the modern version of this coming around until about the 1950s with the first Ruby red laser. Uh and when they had that, they they did actually start doing some testing on a very limited uh number of people, but saw some positive benefits out of it. But nothing really happened to move that forward until the 80s, when you saw Whalen and uh the NASA group uh starting to do testing in space around, it started originally around testing red and infrared uh lights
relative to plants. So can that can we grow these plants in space and and what kind of wavelengths are going to drive better outcomes from plant growth? And one of the things they noticed was the uh kind of just anecdotally as they were running these tests was that the uh the astronauts who were running them uh had uh biomarkers that they were tracking that that came back healthier than the ones who weren't. And uh so they they kind of took that anecdotal piece and dove into it and started doing human testing uh with lasers and light therapy. And I think one of the things that we've seen more recently is that with the advent of solid state uh LED lighting, uh lasers are have traditionally been more sophisticated, larger, more expensive, uh, and because of that less accessible from a device standpoint, uh solid state or digital lighting more accessible from a manufacturing and a cost standpoint. Um, but there are some limitations relative to what they can do from a penetration and a dosing uh profile. So, you know, we've we've spent really
the last five years uh and tens of thousands of hours with our team digging into that there's currently around 7,000 medical trials uh on uh photobiomodulation or light therapy, and there's a there's a really good amount of data around the dosing. And and one of the key outcome drivers is how you dose. How do you deliver the correct number of photons to the correct photo acceptors at the correct depth of tissue? And again, this is something where it's it's kind of developed uh from the 80s with the NASA testing uh and ongoing physiological trials from a medical standpoint, into where we have a much, much more grounded or a much better grounding and kind of foundational understanding of what these triggers are and what are mediating these uh effects from a uh pain reduction, from an inflammation reduction, um, from a soft tissue regrowth standpoint. Uh that there's just really there's really a lot of downstream uh effects that are are triggered by this. And the better you understand the dosing,
the more effectively more effectively you can deliver those.
Eric Malzone: So with what you guys do for us, I mean, is it and um you know forgive my naivety here, but like is it red light therapy? Is it laser therapy? Is there a difference? Like what specifically do do you guys do?
It's a great question. Uh so there's there's a number of different uh terms in the medical literature, even. And so what happened around, I believe, 2015-2016 is they they tried to consolidate a lot of these terms into a uh kind of more of an umbrella term, which is photobimodulation. So photo light, uh bio kind of your physiology and modulation changing. So how are we changing your physiology with light? Before this, uh this was separated into LLLT, so low-level laser therapy, RLT, uh red light therapy. There's there's a number of different kinds of subcategories of this, but uh essentially right now we kind of roll everything under photobiomodulation. We've found that uh using laser therapy for treating internal tissue, so the soft tissue benefits and kind of the internal uh tissue uh treatments that we make for reducing pain and inflammation uh are much better suited to lasers and infrared and a couple of different wavelengths of infrared
uh that allow us to penetrate more effectively. But one of the things that we spend a lot of time on is when we came in, we started developing our product, uh, even the clinical level, that there was a gap between the engineering side and the physiology or medical side uh relative to uh the the metrics that you're measuring for kind of power levels. And so everybody was using different terms. It's very heterogeneous from a uh comparison standpoint. So one of the things we've seen that the research side has been doing is trying to move more towards homogeneous uh metrics for this, but the metrics that are being used for this are very uh broad. Uh so as an example, irradiance and power density are two commonly used uh metrics for measuring how much power is being delivered optically. These are interesting, but there's there's there's a number of different ways you could do those. And so as an example with our products, we've had uh with our first uh our products are modular and wearable. So with our first modules,
we had slightly more powerful lasers and the same amount of power coming out totally, but we've split this into smaller, uh, smaller lasers now. And the the outcomes that we had from our observation studies were uh you know substantially, I want to say high 20s, low 30% better from an inflammation reduction. So even within the given metrics that are in the scientific community right now, we felt that there was a gap that we could fill for how photons are delivered to the photo acceptors directly. And so we've spent a lot of our time kind of going back in and using things like Monte Carlo models from a mathematical standpoint uh for modeling and then baselining in real life uh with metrics like nitric oxide. Serum nitric oxide is something that we use quite uh quite frequently for kind of baselining what we expect from our mathematical models from a photo acceptor trigger for signaling versus what's like what are we expecting and what's happening in real life? And and if we're wrong, why are we wrong? Let's let's go let's go fix these problems. And so again, I I don't
we have not seen other photobiomodulation device manufacturers modeling the delivery of photons to that level of I guess uh resolution or or care. Uh but for us, this is you know, this is what drives the outcomes. And so it's really worth it from a time standpoint to invest our medical and and uh technical teams into building these models and then dialing them in so that we're improving these outcomes over time.
Eric Malzone: Got it. Okay. So uh explain it to me, the layperson of Sibleton. Right. So why should I be looking at your products, your services, red light, photo modulation as a category? Like what are the benefits, you know, and you know, it's one of these things I'm I'm curious about too is I feel like people love immediate gratification with with their, you know, when they invest in stuff like this. Like they want to feel, you know, you get a uh a Theragun or a hyper ice, you know, you know, like you feel it right away, right? Like it's it's immediate. But this stuff so far, from my experience, it's it's it's not quite so immediate, but maybe it is for you. So yeah, explain in lay person terms like what are the benefits here? Why should people be paying attention to this? And then yeah, you know, how how sticky is it from a consumer standpoint?
I think that makes makes great sense. So one of the things that that I think works best to kind of set the context for this is uh comparing it with existing treatment modalities. So uh two of the things that if you go to your doctor, there's this it's one of the things that we we fight on a daily basis is inertia. And it's it's uh it's kind of swimming against the tide, but hoping that that we can get enough people swimming against the tide that we can turn the tide, if that makes sense. But one of the things that we've noticed is medical, and particularly with our older cohorts who have things like osteoarthritis, where you have uh ongoing chronic pain and inflammation that are driving degradation of tissue. The gold standard for this from a medical community treatment right now is ice and NSAT. And I I, you know, we we find this very irresponsible uh in general because the NSAIDs do a couple of things. One which is directly at odds with what you'd like to do if you're taking them for chronic pain in your knee joints or or in your shoulder joints, is increase the degradation rate
of the actual joint over time, which is you know, it kind of seems like this is that that that should that should be a red flag, just a, hey, this might decrease the pain for me short term, but um longer term, this is going to cause my my joints to degrade uh more rapidly. But uh to answer your question more directly, the if people are taking NSAIDs, the laser therapy is more effective. Uh that there's been a number of head-to-head studies uh comparing inSAIDs and and uh pain inflammation pharmaceuticals uh for uh particularly for inflammation-driven pain. So if you have something where there's a a mechanical uh kind of drive for the pain, pinched nerve, uh the light's not going to necessarily help the pinched nerve. But that pinched nerve causes a huge amount of uh tissue degradation around it by having so much inflammation, by triggering inflammation. And that's really where we we can actually offer uh help. So getting people out of pain and inflammation uh in a in a
much uh faster, but also a much longer term and more health beneficial way. Uh so if you're if you're able to uh you know compare these one-on-one, and there's some very good studies, and I'm happy to kind of shoot those over as well. If you have, for example, knee osteoarthritis, your knee tissue, your cartilage in your knees is degrading faster than it would otherwise. You you have a homeostatic uh balance in your knees for how fast you're growing this tissue versus how fast it's it's degrading. If you have inflammation in that synovial fluid around this uh this tissue, then the degradation increases speed and your regrowth decreases speed. And so you just start losing this soft tissue. Laser therapy actually reverses that process. So by removing the inflammation, uh, in the first two to three days, we we see from blood draws roughly 80% of the inflammation is reduced. And what's not reduced is actually acute inflammation that's helpful, that's beneficial to regrowth. So, you know, the the the and we can we can dive in if you like on on uh kind of acute versus
chronic inflammation. But the long story short is that this is this is an investment in being able to regrow tissue by increasing the rate of proliferation for chondroblasts, which are the the fast front edge, uh fast growing front edge cells of your soft tissue like cartilage or ligaments, and by uh by decreasing inflammation dramatically. Uh and that's not something that pharmaceuticals do. And it really uh again, our our hope for this was to be able to reduce the price of uh laser therapy devices and also make them more sticky by making them have less friction points. So uh we we've made it so you don't have to have a big laser set up on your desk, on your desktop. Uh, we we've been very lucky in the technology we've been able to adopt for this vertical cavity surface emission lasers, have made a huge leap in reducing cost and size of lasers uh over the past five years. And and we've been very lucky to be able to adopt those and bring them into something that is now wearable and that can actually treat this internal tissue more effectively.
And so our assumption is that if people are educated about the issue and this data is put in front of them directly, and you can say, you know, you're going your knees or your your joint tissue is going to degrade if you start if you keep taking these NSAIDs, but there is a solution that can reduce the pain inflammation and actually help you with regrowth, that they're going to make uh rational decisions and invest in their long-term health.
Eric Malzone: Awesome. So let's let's maybe boil it down to like a green little example, my knees, right? My knees take a beating. I ski hard, I ski a lot. When I'm not skiing, I'm you know, hiking, biking, you know, with a pack, all kinds of stuff. Stuff that, you know, as a 47-year-old, I know the first thing it's gonna go is gonna be my knees. It's not bad yet, but is that like if I, you know, instead of after a long day and my e my knees are achy, is this something instead of like, you know, an ice pack and maybe an anvil, I would revert to this and this would be a much better and effective option? Like how how would those two things compare in the actual you know, short-term and long-term health of my joints?
It's it's what we the the analogy we use for this is uh it's it's putting out the fire in the kitchen versus taking the batteries out of your fire alarm. Uh, if you're taking in saves, you're essentially taking the batteries out of the fire alarm, your kitchen's still on fire. Like your knees, they may not hurt as bad, but it's it's you know, your the house is still burning down. And so what we'd love to be able to do is say, hey guys, leave let it let it beep. It's for now, it takes a little while. You know, yeah, to your earlier point, we see around larger joints uh that it takes two to three weeks for people to start seeing kind of the meaningful well, what we see on average is, and I need to reference our our data for the latest, but I in in orders of magnitude terms, seven out of ten in pain for the knees, going down to about a three over two to three weeks uh for people who have been in severe chronic pain for the joints. The longer-term version of that, though, is that you're actually regrowing the cartilage and helping yourself build better tissue, helping yourself build longer-lasting joints and making an investment in being able to move functionally longer.
Because when you have uh in inflammation is a terrible scourge in our bodies and it doesn't stay local. It's you know, if you've had uh pounding your knees or knee injuries from skiing or from football uh or from you know tennis or or whatever, whatever sport, uh I've done the same thing grappling. I've torn my meniscus and I I've had long-term chronic inflammation in the knee that I I I couldn't deal with because there just wasn't anything out there to be able to really treat that. You now have an option for being able to reduce that inflammation. And again, that's not just impacting that local joint tissue. One of the things that we've seen coming out of the literature, and again, it's it's it's really not commonly known, uh, is that this inflammation actually has systemic, so regional and systemic level uh impacts as well. And so, as an example, one of the things that we've been doing with some NFL players that we work with is measuring those who've had ACL and ACL tear and ACL surgery. And you'll see the tissue in the quad above
that uh be 1.5 to two degrees colder, even five or six years after the injury. Uh, and they've they've rehabbed it and they've they've done their work to make this happen. But what's happening is that inflammation is triggering out of the knee and impairing the blood delivery in that in that region. And the second piece of this that's even scarier is 10 years on, there was a very large study on NFL players. We didn't, we didn't run this study, but it it's a very telling one. Uh, and we have run some studies on on this subject since then to kind of delineate what are the mediating factors for this. Uh the ACL, the ACL tears for NFL players in a 3,500 player study, uh increased mortality by cardiovascular disease within the next 10 years by 50%. And that's yeah, that's that's already taking like so. This is this isn't something where they haven't been able to rehab the knee and they're not moving as much, or they're not, you know, they're they're still moving, they're still training, but it's the inflammation and what It's come down to with the studies we've had since
then, and not just us, there's a number of different groups looking into this, uh, into this space, but uh the the cardiovascular tissue is actually losing shear strength uh resistance. And so uh shear strength is is one of the metrics they use for as blood's going through your blood vessels, it's going at a kind of a perpendicular to the tissue. How much pressure uh that puts on and how much uh the uh the flexibility or or elasticity of the cardiovascular tissue uh and and the robustness of the tissue allows it to withstand is called a shear strength. And what we see is that when when people have this local inflammation, it trickles through the rest of the body and causes really, really damaging long-term impacts. And so, you know, again, if we can get people away from taking the batteries out of the fire alarm and and really get them into a place where they have a fire extinguisher to go put this fire out, it's not just going to make a big difference on the on the local knee tissue. It's going to make a lifelong
difference. And that's that's our real goal for this is to provide people with a systemically beneficial outcome relative to what they have from pharmaceuticals.
Eric Malzone: Awesome. Awesome. I want to jump into the commercial opportunities here in a minute, but I guess a couple more follow-up, like just pulling back for a second, when I look at like, you know, I guess, you know, this is more of a laser therapy, right? Red light, but laser specifically. What about like red light therapies? They're having a moment, right? Especially with this wellness boom that we're seeing. You know, a lot of places are, you know, people are getting uh red light saunas, or you can go to, you know, see a local gym here, just went from a fitness gym to a wellness place, right? So everybody's jumping on the wellness badwagon and red light therapies tend to be, and even consumer goods. Like I was telling you about I had a one of those JU panels. So, you know, is there is there a correlation between what you guys do and kind of these these more you know mainstream red light therapies? Yeah, explain, explain the differences.
So we we what how how we kind of think about the the red light panels is that LEDs are easier to design around, they're more of a commodity product, they require less sophisticated engineering, and they require less regulatory. So this is going to be what's the volume in the space uh from a a kind of how people are introduced to uh red light therapy. The downside for these is that LEDs emit uh light and and what's what's called a lambertion pattern. Uh so they're essentially dye that emit light in all directions that get packaged into a small cup or a a uh an electrical component that can go on a PCB uh that are called uh PLCC packages in most cases. That that restrains that 360-degree emission back into 120 degrees. It's when you're dosing with a a panel, uh the downside is if you're the the emission is very wide. So if you're treating things like skin level, uh if you want to have more type 2 collagen and have less
wrinkles as an example, it's a it's a good anti-aging uh treatment. There are a couple of other wound healing, there's another great application for this. Uh so if you have a cut on your arm and you want to want it to heal faster, there's amazing data on this type of thing from a wound healing standpoint. What it doesn't do though is penetrate like laser light. Laser lights is what they call collimated, so it's very direct and and essentially in a line. Uh so there's two things about how we approach this that are a little bit different than the panels. One is there's we're we're using lasers, so the penetration internally is going to be better. And two is that we we made it wearable so that it's at the skin level so that our dosing models are more effective. The when you're when you're trying to build dosing models for how photons This episode of The Future of Fitness is brought to you by our friends at Wattify.
Eric Malzone: I own gyms for the better part of a decade. There are a lot of options when it comes to gym management softwares, and the cost and stress of migrating from one to another is tremendous. Trust me, I get it. That's why making the Switch needs to be an absolute no-brainer. What if unlimited tier offers all their premium features for zero monthly fees. Now that is compelling. No membership caps, no hidden costs, just pure value. With WattiFi's Free Unlimited Tier, you can increase your profit by 25% tomorrow. 25%. Their all-in-one customer retention platform is designed to help you keep your members engaged and coming back for more. In fact, Watafi run businesses have an average retention rate of 96%. Join over 5,000 businesses that trust Watafi to revolutionize their fitness operations and create state-of-the-art fitness experiences. To learn more or to speak with the Watafi team, go to Watafi.com forward slash
Eric Malzone: future of fitness. That's w-odify.com forward slash future of fitness. Now on to the show.
So just as an aside, a small branch off for this, the reason that dosing is so important is that your body responds to light like it does to pharmaceuticals on what they call a biophasic dose curve or an Arnt Schultz curve, which is essentially a sine wave that the more that you're taking of either this dosing of light or of pharmaceuticals, the better the outcomes are until you reach an apex and then it goes back down. And with the pharmaceuticals, it goes way back down below zero. With the with the light, it goes back down to zero. So uh getting the dosing correct is very important. And there's something called the inverse root square law, where uh they've done a very good job of explaining this with a a uh a fun YouTube video that I can I can send you a link for. But essentially think about shooting uh shooting butter at toast. If you are if you're trying to cover the toast and you have a butter gun and it sprays it out, uh like if you are yeah, the butter gun sounds amazing. This is this is the most uh intuitive way I've I've found about talking about the inverse
root uh square law. So uh if you if you've got if you're two inches from if the the butter gun has a has kind of a two-inch distance from the toast, then it hits it and you've got you're completely covered. If you're two inches back, you can now cover four uh four toasts, or if you're six inches back or eight inches back, you're covering a whole wall. So like the the difference in dosing from a from a photon delivery standpoint with the panels relative to treating at the skin level is is is very difficult to manage uh and uh is non-optimal. With that said, we we would much prefer to see people using panels than nothing. Uh it it's a way like it's it's kind of what we think of as a first generation product because it's easier to deliver, it's easier to design. You you strap a bunch of LEDs to a board and it's gonna get people some some, it's not gonna likely get them to the apex of a dosing standpoint, but it's gonna get them something above zero. And that's that's still better than kind of turning to pharmaceuticals for a a uh which is likely going to leave
you below zero.
Eric Malzone: And uh you mentioned it earlier, and I'm just curious because I live up here you know pretty far north, uh winters are gray, but seasonal effective disorder, is red light therapy a uh a solid uh remedy for that or an option for to fight that?
What I've seen is the most effective uh versions of those are certain blends of whites. So white's a white's a blend of a lot of different colors. There's certain reds that you need in that blend uh that that correlate actually with uh sunrise. Uh, you know, there's there's different because of of how light comes through uh the atmosphere, you get more red in the mornings. And uh so you can build those in. And and there are some some very good white products uh that are uh white white uh LED emission products that are used for seasonal effective disorder. I a uh we we joke our head of research.
Eric Malzone: The spurting lamp?
Yes.
Eric Malzone: Like the spurting lamp, the vitamin D pants. Yeah.
Yes. Yeah, we joke our our uh our head of research uh who's who's uh just starting in as a PhD candidate, he's a very smart young man, but he's up in Finland. And we're like, we've got to send you at least three or four of those because it's it's uh it is dark up there a lot of the year.
Eric Malzone: Yeah, it's it's pretty great here. And you know, I so anecdotally, right? I've been using the panel for about uh red light panel for two or three months, but it sounds like I need to step up my game here after talking to you for us. The uh generally by January here in northwest Montana, I will get some sneaking depression, right? It just kind of comes in. And but I I'm aware of it now. After the first couple of years here, I was like, why am I just bummed out? You know, but I I have noticed like I haven't almost none of it, you know, since I started using it. So that's got to be something. I also have a spirit vitamin D land. But I think it's it's tough. You know, we talk about all the benefits of vitamin D and sunshine nowadays and you know, like all the like the Huberman effect of all these wellness podcasts and and outlets where people are starting to learn about it. But it's hard for people who live in northern climates to get you know this optimal right lifestyle of everything. So yeah, I'm always I'm always curious about that. Of course, let's talk about the commercial opportunity. So you guys are doing a direct-to-consumer, is that right? Or do you have a B2B model? Tell me how you're how you're going to the market and maybe just give us some insights into like,
Eric Malzone: you know, how long the business has been around. You know, did you guys raise money? Are you bootstrapping this? Like, how are you taking what's the strategy for for going to market and all of those business, business-y things?
Uh great question. We started the company about three years ago. We delivered our first products. We actually, it's for both my partner and myself, we had built uh B2B companies before, but it's our first direct consumer brand. And so to be able to understand our uh to build a community and understand and interact with them more effectively, uh, we went to market with the first product through Indiegogo campaign. So the crowdfunding was great. Uh, we had a uh a really uh exciting time uh kind of sitting down. We I think we we totally met with a hundred different potential users, many of whom end up being users, uh, to understand how they thought about their pain, what kind of language they used, and what we could do to be able, from a product design standpoint, to be able to help them build habits in a meaningful way. Uh, because it really is the consistency of use that's going to drive the best outcomes with the device. So we, I want to say 2021, October 2021, we launched the product. Uh, August of 2022, we started delivering. And since then, we've delivered almost, I think, almost 20,000,
so 18 or 19,000 devices worldwide. Uh, and it's just been scaling kind of year on year. And uh we we didn't, with our unusual take on building the business and and really not focusing on the commercial outcome, we wanted to avoid uh taking on uh heavy investment early, uh kind of from from VC or private equity. And so we offered our community a uh an opportunity to invest in. And we've we've taken on half a million dollars uh through a crowdfunding, an equity crowdfunding raise. And we're we're right now, aside from that, uh essentially bootstrapped. We've we're delivering a couple thousand devices a month right now. Uh it's been growing very, very well. And we're seeing that you know, really it's having kind of a network effect of people using this, seeing good results, and then uh, you know, telling their friends, and and we see these kind of geographical blossoms around people and their use cases because of this. Uh, we are kicking off a uh B2B, uh, what we're calling our medical professional reseller network
this year. Uh we weren't planning on doing this, and and we actually had to be slapped in the face uh around a hundred times uh to really take note of it. But what happened was uh we started testing with this last year, last October, based on around a hundred different medical uh practitioners had written in or called us and said, you know, I'm an orthopedic surgeon, I'm a chiropractor, but I'm also a triathlete. And I have this uh repetitive stress injury like patellatendonitis. I got great results from using your devices. So I bought five for my clinic. And, you know, how do I uh how do like my patients now want to buy them? How do we work together? So having been slapped in the face with that, you know, a hundred times, uh we we started building out a beta uh test for it, and it performed way better than we expected. And so one of the things that we noticed with this was that two of we have we have three different groups that we find uh kind of ourselves connecting with, just kind of synergistically, uh young uh performance-based athletes, and that's you know, a lot of that's CrossFit and triathlons and NFL and NBA and
this type of thing. And then middle-aged guys like me who would like to keep doing and uh, you know, kind of uh my wife gives me a hard time. Um I'm still playing rugby and and CrossFit, which is you know, likely the two things that are gonna get you injured the most. But uh I'd like to keep doing those for the the, you know, for the the near future as long as possible. And so we we find ourselves connecting with those uh that cohort very well. One of the things we've never been able to do from a digital marketing standpoint is connect in and tell our story to people who are older, so 55 plus and have osteoarthritis or chronic pain. They don't like being targeted digitally from a marketing standpoint, but what they do like is, and they become flag-waving users, uh, is if they go into their doctor and the doctor says try this, and they can try it and see the results in clinic, then they buy. Uh, and and it's been, you know, it's it's the only way that we've found. And I think that's gonna be a large bulk of what we find from a purchase uh kind of journey standpoint is that uh we're not going to sell online to to these these kind of older cohorts. Uh they're they're going to see
they they they're the kind of show me cohort. They're older, they don't want to hear about the story, they don't want to watch the YouTube video, they want to see it work. And so when they see it work, they go in, they buy, and they tell their friends. And it's it's been amazing the results that we've seen through our medical practitioners today.
Eric Malzone: Yeah, it makes a lot of sense. I would imagine like sports performance uh centers would be an interesting option for you guys too, right? I mean, uh, you know, there's a lot of athlete rehab, and I mean, just recovery as a as a category right now is is so is just so popular for good reason, right? I mean, it's something in the United States we've been lagging behind other countries globally and for so long is like we train, train, train, train, train, but no one talks about recovery. Finally, recovery is kind of the moment. But yeah, imagine sports performance. Are you are you getting some intakes on CrossFit makes a ton of sense? I mean, CrossFits will buy CrossFitters will buy anything to keep CrossFitting, right? I know from from exam from personal experience.
Yeah, no, I I same. I uh sports performance. Sports performance is is uh is great. I I I think two of the things that that I should mention relative to sports performance that have been that we've tracked and measured that are super interesting uh from kind of a strength and conditioning coaches or or kind of PTs and physios is uh performance, so uh muscle recovery. So if you're if you're doing really intense heavy workouts, one of the things that limits you uh from coming back and training effectively for the adaptations that you'd like to make, uh whether it's hypertrophy or strength or power, whatever you're training for, uh, is the muscle inflammatory inflammation that you trigger by way of this exercise. And so uh, you know, one of the kind of one of the things we hear about this quite a lot is, you know, if I if I'm not triggering muscle inflammation, am I going to reduce or remove the amount of uh adaptation for strength and hypertrophy that I'm going to see? And it's actually the opposite direction. So two of the things that we measure for this are uh C reactive proteins and creatinine kinase, uh, which are
two commonly measured um muscle inflammatory markers. And we reduce uh, not always get them backwards, but we reduce one by by over 60% and one by over 80% uh overnight. And so meaning, you know, and and you know how that presents, you know, for me from a training standpoint, if if so it also reduces late onset muscle soreness, and that that's really nice as well. But a lot of times the professional athletes are looking more at the the performance benefits than they are necessarily at the the soreness, which they've kind of written into their their journey. But for me, if I go do a lot of front rack lunges as an example, uh to kind of hips and and quad strengthening, you know, you go do 200 uh front rack lunges in a day, you you don't think you know you're gonna be sore. You know you're triggering uh real, real significant muscle inflammation in the two largest muscles in your body, three largest muscles in your body. And uh when you can reduce that delayed onset of muscle soreness, but also when you can reduce the time that it takes you to recover from this and to get back into training, uh, these strength
and condition coaches are loving it. They're they're uh, you know, they have a hard time. You know, some of the guys who are our strength and condition coach for the The Washington Command as an example loves laser therapy. He'd love to have his guys in a bed uh kind of uh doing something with this. He'd love them to have them on some of the clinical level devices, which they have in their facilities. It's hard to get people in into that from a day-to-day consistency. And so what he's found is when he he gets the guys in for tape uh to watch tape with them, and he'll just strap everybody on with the uh with the move plus and make sure that they are recovering better from these these really intense workouts that they're doing because it's it allows them, it's almost like a performance-enhancing drug from an outcome standpoint. You could actually just go through your your power and strength increase curves that much faster because you're recovering that much faster.
Eric Malzone: Yeah, interesting. So I'm looking at the the product itself. I mean, is there is there like describe the product line? I mean, is there one product for like every joint in the body or like how yeah, how are how are you guys laying off the product line?
It is, and just to kind of give an idea from a visual standpoint, here's the uh so it's a it's a strap uh system that we've put on with three modules that come with a standard product. Uh and it does work for we we have an extender uh module here that I I don't have with me uh that can extend it around your body. So you can kind of put these down towards minimal distance between each other. And I I, for example, use it every day on my lower back and my gut for gut health. It's really nice. And actually, it's one of the things that well with the gut health season load of really yes. Uh it's our next product. This this actually already makes a big difference. I I use it the 808 nanometer uh makes a big difference from an inflammation standpoint in your gut and also triggers dopamine signaling. Uh, there's there's uh a couple of different uh clinical and and academic teams that are are looking on looking at applying that to Parkinson's and seeing very good results relative to treating the gut for Parkinson's because of the the dopamine gap that you have with Parkinson's. For me, I just feel better on a daily basis. I've uh long-term crossfitter and I'm six foot three, and
so my lower back uh with the amount of Olympic lifting and deadlifts is it's you know it's not fantastic, at least, you know, once every other month. And uh, I found that just treating every day the the uh lower back tissue for pain and inflammation keeps me healthier longer. And if I do tweak something because I'm I'm kind of getting to my ego with the lifting, then it gets me back into lifting a lot faster as well. Yes, yeah, unfortunately, it's hard. It's hard not to.
Eric Malzone: Yeah, and 6'3 isn't the best frame for CrossFit uh either. So yeah. So it's guys like our 5'6, 5'7, right? Short arms, long torsos. And yeah, so you got you got a lot of, so you got CrossFit as a is really popular. I'm just looking at your website too. Like you you have some of the biggest names. I mean, Brooke Wells, Sarah Sigmund's daughter, like these are these are a big deal. I mean, where do you think? I mean, you mentioned the uh you know, the practitioner angle on the B2B side, but where do you see the biggest markets, you know, maybe for 2024 that you guys are targeting or you think have the biggest opportunity?
I think the medical practitioner ones, uh, you know, we we all of us as founders, particularly Tom and myself, uh, our parents were in their 70s. And one of the reasons we really like this, you know, A, the concept of the mission of the company, but B, this technology is that we can really make an impact not just for our ourselves and extending out our kind of ability to go uh CrossFitter or play rugby, but it also makes a huge impact from a lifestyle standpoint, from a quality of life standpoint for the older cohorts. And we've been it is it was frustrating to try to to address those markets and have them completely dismiss the the digital marketing side. And so we've been so excited to be able to work with our medical practitioners and and I've actually gone in and do some uh some clinic level visits with these guys, and like the the stories that you hear back from these patients, it's exactly why we're at work every day. Like this is this is why it's a mission-driven company. Like you, you you know, building any small business, you get beat up, there's there's a lot going on, there's a lot of friction to kind of reverse the inertia that's existing. And finding the energy to do that can be uh uh
can be difficult sometimes. But you know, we come into work and and you see these stories from people and you hear these stories directly from people in these clinics, and it's it's life-changing. It's just I I I can't get out of bed fast enough to go to go do what we needed to do to make that happen. So for me, that's the most exciting is these older cohorts being able to actually take this on and and uh and adopt it is is just super powerful.
Eric Malzone: Right on, man. Oh good. I'm I'm I I feel your excitement. I like uh what you mentioned you alluded to earlier as far as like product extension, mentioned like it got one, but what do you what do you foresee as like what are some of the newer products that you're gonna come out with from in the next foreseeable future?
So uh I'll try to keep myself contained a little bit, but the the product that I actually wanted to start the company with is a brain product that we can uh uh treat transcranially, and there are a number of neurological pathologies like ADHD, depression, uh chronic anxiety, bipolar addiction, and then even longer-term uh things like uh different flavors of dementia like Louis Body syndrome, Parkinson's, uh Alzheimer's, where treatment has already been shown to be effective. But our one of the things to take it back to our mission and where we're going to be going with this longer term is we have to hold ourselves accountable not just for the number of people we get this to, but the the measurement of how we're impacting their quality of life. And so one of the things we've been working on uh with our tech team is a spectroscopy-based solution, uh, which is essentially shooting lasers in and then measuring back out with sensors the interaction that that light has had with tissue. And we have a really powerful system that we're building around
how you can measure metabolic function or impairment in the brain. And when you can see where your brain uses or doesn't use energy very well with these different systems, whether it's, you know, oxygen is one of the proxies. We use how your brain delivers oxygen, we can measure directly. Cytochrome C oxidase is an enzyme in the phospholactid bilayer of your mitochondria. That's a good measure for mitochondrial function. Lactate, there's a number of different systems that kind of overlap. Your brain, you never want your brain out of, you know, if your if your arm runs out of energy for a little while, like you're kind of okay, if your brain runs out of energy, there's a ton of redundant systems in your brain. So long story short, we're we're kind of pulling together how to map all of those into these 3D pictures and then treat on an individualized basis around what what area of the brain has this impairment and where we can impact it and how your body responds to that. And so essentially you have this 3D picture of before, during, short-term, middle term, long-term. And we won't be able to launch
that until next year. But it is I for me, it's it's one of the most exciting technologies, not only that I've been involved in, but that I've seen in in the last 20 years. It's going to really change people's lives.
Eric Malzone: Wow. Awesome, man. Well, the last question I always ask people on the show to Forest is like, what do you need right now? You know, when you're you're talking to the community of fitness, health, and wellness, you know, industry professionals. Like, what would you like to hear from people about and how would you like them to reach out to you?
Uh reach out. I I uh one of the things that that my partner Tom and I kind of took on as a commitment to you know, to our mission of really not just trying to shift products, but uh trying to help people change their lives is if people are not getting what they want out of this or if they have questions about the technology or whatever, we have both of our calendaries uh available uh publicly. So that if if you have a problem with the product or if you have a problem that that would keep you from buying it or adopting it, call us. This is something that that we're we're happy to jump on a call with you and talk about. I don't know how many how many more years we can we can keep that up because it is ramping up in the number of calls we're getting in for it. But the the uh what we really need is you know, let's let's start talking more about what the limitations are for this current system of pharmaceuticals. Uh and you know, let's let's make people aware of what they're losing and what they're putting themselves at risk because of these pharmaceuticals. And then let's talk about what we can do to fill the gap, to take it into a more manageable long-term solution that's going to provide better results for everyone. I
really, you know, that's that's if we could ask for everyone kind of to, you know, just read more about this, contact us about it, tell us how we can make that more digestible and palatable for uh anyone who needs that kind of pain relief or or has chronic pain, you know, that's that's what we're here for. So, you know, again, how however we can engage to support that, I'm happy to do it. But yeah, that's the getting getting the education out is the the big ask.
Eric Malzone: Yeah, yeah. Education comes first, man. It's great, uh, it's a great market approach. And for people uh listening, so the website is k-in e-o-n dot io. And uh yeah, thank you so much for joining. I mean, I feel your excitement. I love that we just geeked out on red light therapy for you know 45 minutes. That's really fun. Uh really dispelled some some things uh missed that were swimming around my head. So really appreciate it. And uh yeah, ladies and gentlemen, Boars Smith. Thank you so much here. Really appreciate it. Hey, wait, don't leave yet. This was your host, Eric Malzone, and I hope you enjoyed this episode of Future of Menace. If you did, I'm gonna ask you to do three simple things. It takes under five minutes and it goes such a long way. We really appreciate it. Number one, please subscribe to our show wherever you listen to it, iTunes, Spotify, Castbox, whatever it may be. Number two, please leave us a favorable review. Number three, share. Put it on social media, talk about it to your friends, send it in a text message, whatever it may be. Please share this episode because we put a lot of work into it.
Eric Malzone: We want to make sure that as many people are getting value out of it as possible. Lastly, if you'd like to learn more, get in touch with me, simply go to the futurofitness.co. You can subscribe to our newsletter there, or you can simply get in touch with me as I love to hear from our listeners. So thank you so much. This is Eric Malzone, and this is the future of fitness. Have a great day.
Why this conversation matters
Show notes by Dani
In this episode of the Future of Fitness, host Eric Malzone sits down with Forrest Smith, a seasoned entrepreneur and co-founder of a company pioneering the use of red light and laser therapy for neuromuscular pain and inflammation. Forrest shares his journey from starting multiple startups to founding a company focused on creating systemic health and wellness solutions. He explains the science behind their innovative device, which aims to make laser therapy more accessible by reducing costs and making it wearable. Discover how this technology can potentially replace traditional pain management methods like NSAIDs, offering a safer and more effective alternative.